||Gilead Sciences Inc
Growth of $10,000.00
With Dividends Reinvested Into GILD
Gilead Sciences is a research-based biopharmaceutical company that discovers, develops and commercializes medicines. Co.'s primary areas of focus include viral diseases, inflammatory and fibrotic diseases and oncology. Co.'s products include: Biktarvy for the treatment of HIV-1 infection in certain patients; Vosevi®, a single tablet regimen of sofosbuvir, velpatasvir and voxilaprevir for the re-treatment of chronic hepatitis C virus infection in adults; Vemlidy® for the treatment of chronic hepatitis B virus infection in adults with compensated liver disease; and Yescarta (axicabtagene ciloleucel) for the treatment of adult patients with relapsed or refractory large B-cell lymphoma.